πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,022 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11603519

T-cell receptor

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597928

Nucleic acid complex

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596688

Predicting outcome of treatment with an anti-Ξ±4Ξ²7 integrin antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596671

Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with in

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583526

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11584737

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583563

Adeno-associated virus formulations

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11576863

Formulation of an antibody and use thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571466

Compositions and methods for treating Gaucher disease

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11564979

Stabilized liquid and lyophilized ADAMTS13 formulations

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11564992

Nucleophilic catalysts for oxime linkage

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11560372

Heterocyclic compounds useful as modulators of acetylcholine receptors

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11530393

Compositions comprising iduronate-2-sulfatase

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529395

Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by a

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529363

Methods of treating cancer in pediatric patients

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512066

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505620

Methods of detecting plasma kallikrein

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492388

Viral vectors encoding recombinant FVIII variants with increased expression for gene thera

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11478511

Lymphocyte biomarkers for determining the clinical response to cell therapy

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464869

Non-adult human dosing of brentuximab vedotin

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11465994

MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459325

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453661

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11447488

Heterocyclic compounds

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted